Articles producció científica> Medicina i Cirurgia

Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

  • Identification data

    Identifier: imarina:9366508
    Authors:
    Masana, Lde Isla, LPMoya, GD
    Abstract:
    Background and aims: Despite considerable evidence that lipid-lowe ring therapies (LLTs) afford clinical benefit, the control of low-density lipoprotein cholesterol (LDL-C) is suboptimal, and available LLTs are underused, especially in patients at high and very high cardiovascular (CV) risk. This study assesses the real-world LDL-C target attainment rate in patients on LLT before experiencing a first major acute cardiovascular event (MACE). Methods and results: The HEARTBEAT was a retrospective, multicentre observational study. From March to June 2021 a total of 334 patients on LLT who had a first MACE while being on statins were included in the study. Of these patients, 83.2 % had a high (40.7 %) or very high CV risk (29.0 %) prior to MACE. Overall, 87.5 % and 89.7 % of the patients at high and very high CV risk, respectively, failed to reach the LDL-C target. Regarding LLTs, only 11.8 % and 19.6 % of the patients at high and very high risk had received high-intensity LLTs prior to MACE. It was estimated that if these patients had reached their recommended LDL-C targets, the risk of MACE may have been reduced by a median of 24.5 % and 23.2 % in patients at high and very high risk respectively. Conclusions: Patients who suffer a first MACE while on statin therapy often were at high/very high CV risk. Despite their risk, LDL-levels and being on statins they are undertreated, and too far from lipid targets. A proper use of high-intensity LLTs led to an increase attainment of LDL targets and lower CV events. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This
  • Others:

    Author, as appears in the article.: Masana, L; de Isla, LP; Moya, GD
    Department: Medicina i Cirurgia
    URV's Author/s: Masana Marín, Luis
    Keywords: Spain Safety Risk Primary prevention Population Participants Metaanalysis Lowering therapy Low-density lipoprotein cholesterol Lipid-lowering therapy Ldl-cholesterol Efficacy Coronary-heart-disease Cardiovascular risk
    Abstract: Background and aims: Despite considerable evidence that lipid-lowe ring therapies (LLTs) afford clinical benefit, the control of low-density lipoprotein cholesterol (LDL-C) is suboptimal, and available LLTs are underused, especially in patients at high and very high cardiovascular (CV) risk. This study assesses the real-world LDL-C target attainment rate in patients on LLT before experiencing a first major acute cardiovascular event (MACE). Methods and results: The HEARTBEAT was a retrospective, multicentre observational study. From March to June 2021 a total of 334 patients on LLT who had a first MACE while being on statins were included in the study. Of these patients, 83.2 % had a high (40.7 %) or very high CV risk (29.0 %) prior to MACE. Overall, 87.5 % and 89.7 % of the patients at high and very high CV risk, respectively, failed to reach the LDL-C target. Regarding LLTs, only 11.8 % and 19.6 % of the patients at high and very high risk had received high-intensity LLTs prior to MACE. It was estimated that if these patients had reached their recommended LDL-C targets, the risk of MACE may have been reduced by a median of 24.5 % and 23.2 % in patients at high and very high risk respectively. Conclusions: Patients who suffer a first MACE while on statin therapy often were at high/very high CV risk. Despite their risk, LDL-levels and being on statins they are undertreated, and too far from lipid targets. A proper use of high-intensity LLTs led to an increase attainment of LDL targets and lower CV events. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    Thematic Areas: Serviço social Saúde coletiva Nutrition and dietetics Nutrition & dietetics Nutrição Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Enfermagem Endocrinology, diabetes and metabolism Endocrinology & metabolism Educação física Ciências biológicas ii Ciências biológicas i Ciências ambientais Cardiology and cardiovascular medicine Cardiac & cardiovascular systems
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: luis.masana@urv.cat
    Author identifier: 0000-0002-0789-4954
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.nmcd-journal.com/article/S0939-4753(23)00383-6/fulltext
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Nutrition Metabolism And Cardiovascular Diseases. 34 (1): 90-97
    APA: Masana, L; de Isla, LP; Moya, GD (2024). Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition Metabolism And Cardiovascular Diseases, 34(1), 90-97. DOI: 10.1016/j.numecd.2023.09.022
    Article's DOI: 10.1016/j.numecd.2023.09.022
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2024
    Publication Type: Journal Publications
  • Keywords:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine,Endocrinology & Metabolism,Endocrinology, Diabetes and Metabolism,Medicine (Miscellaneous),Nutrition & Dietetics,Nutrition and Dietetics
    Spain
    Safety
    Risk
    Primary prevention
    Population
    Participants
    Metaanalysis
    Lowering therapy
    Low-density lipoprotein cholesterol
    Lipid-lowering therapy
    Ldl-cholesterol
    Efficacy
    Coronary-heart-disease
    Cardiovascular risk
    Serviço social
    Saúde coletiva
    Nutrition and dietetics
    Nutrition & dietetics
    Nutrição
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Farmacia
    Enfermagem
    Endocrinology, diabetes and metabolism
    Endocrinology & metabolism
    Educação física
    Ciências biológicas ii
    Ciências biológicas i
    Ciências ambientais
    Cardiology and cardiovascular medicine
    Cardiac & cardiovascular systems
  • Documents:

  • Cerca a google

    Search to google scholar